The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.

Diabetic wounds have elevated levels of cathepsin K, a protease enzyme, which degrades proteins, such as collagen, causing delayed wound healing. By targeting cathepsin K, diabetic wound healing is ameliorated. Methods and devices for treatment include intradermal injection of odanacatib at or adjacent a wound. Methods and devices for treatment include topical application of pharmacological inhibitors of cathepsin K, for example, in the form of gel, powder, or bandage. Other methods and systems include localized genetic knock out of the cathepsin K gene by topical application of a small interfering RNA (siRNA) or antisense oligonucleotide to aid in wound healing.

Diabetic wounds have elevated levels of cathepsin K, a protease enzyme, which degrades proteins, such as collagen, causing delayed wound healing. By targeting cathepsin K, diabetic wound healing is ameliorated. Methods and devices for treatment include intradermal injection of odanacatib at or adjacent a wound. Methods and devices for treatment include topical application of pharmacological inhibitors of cathepsin K, for example, in the form of gel, powder, or bandage. Other methods and systems include localized genetic knock out of the cathepsin K gene by topical application of a small interfering RNA (siRNA) or antisense oligonucleotide to aid in wound healing.

The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.

Embodiments relate to a modified cell comprising a polynucleotide encoding an antigen binding molecule and a polynucleotide encoding an agent targeting one or more extracellular matrix (ECM) molecules. In embodiments, the polynucleotide encoding the agent comprises at least a nucleic acid encoding Cathepsin K (CK), a nucleic acid encoding Neutrophil Elastase (NE), or a nucleic acid encoding MMP7. In embodiments, the nucleic acid encoding NE comprises a nucleic acid encoding NE and a nucleic acid encoding a signaling domain of IL2. In embodiments, expression of the polynucleotide encoding the agent is regulated by hypoxia-inducible factor 1-alpha (HIF1?), nuclear factor of activated T-cells (NFAT), forkhead box P3 (FOXP3), or nuclear factor kappa B (NF-?B).